INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 160 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,346,237 | +38.7% | 126,550 | -17.2% | 0.01% | +50.0% |
| Q2 2023 | $1,691,074 | -13.3% | 152,900 | +5.2% | 0.01% | -27.3% |
| Q1 2023 | $1,951,258 | +10.9% | 145,291 | +2.2% | 0.01% | +10.0% |
| Q4 2022 | $1,759,299 | -7.4% | 142,223 | +4.4% | 0.01% | -16.7% |
| Q3 2022 | $1,900,000 | +40.3% | 136,193 | +38.9% | 0.01% | +50.0% |
| Q2 2022 | $1,354,000 | -22.1% | 98,036 | -8.2% | 0.01% | -11.1% |
| Q1 2022 | $1,738,000 | -9.3% | 106,843 | -9.2% | 0.01% | 0.0% |
| Q4 2021 | $1,916,000 | +9.2% | 117,629 | -0.4% | 0.01% | 0.0% |
| Q3 2021 | $1,754,000 | -26.8% | 118,095 | -1.6% | 0.01% | -25.0% |
| Q2 2021 | $2,396,000 | -6.5% | 119,996 | +8.1% | 0.01% | -14.3% |
| Q1 2021 | $2,563,000 | +282.0% | 111,045 | +2482.4% | 0.01% | +180.0% |
| Q4 2014 | $671,000 | – | 4,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |